ParkinsonCanadaV1, Main, Exploration, bibRecord, 004081

The use of PET in Parkinson's disease

Identifieur interne : 004081 ( Main/Exploration ); précédent : 004080; suivant : 004082

The use of PET in Parkinson's disease

Auteurs : H. Shinotoh [Canada] ; D. B. Calne

Source :

Brain and cognition [ 0278-2626 ] ; 1995.

RBID : Francis:522-95-11842

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Physiologie pathologique, Neurologie, Diagnostic, Tomoscintigraphie.
Wicri :
- topic : Neurologie.

English descriptors

KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (therapeutic use), Aging, Antiparkinson Agents (therapeutic use), Binding Sites, Brain (diagnostic imaging), Brain (metabolism), Brain (physiopathology), Corpus Striatum (physiopathology), Diagnosis, Diagnosis, Differential, Humans, Neurology, Neurotransmitter Agents (physiology), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson's disease, Patological physiology, Receptors, Dopamine D2 (physiology), Substantia Nigra (physiopathology), Tomography, Emission-Computed.
MESH :
- chemical , physiology : Neurotransmitter Agents, Receptors, Dopamine D2.
- chemical , therapeutic use : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Antiparkinson Agents.
- diagnosis : Parkinson Disease.
- diagnostic imaging : Brain.
- drug therapy : Parkinson Disease.
- metabolism : Brain.
- physiopathology : Brain, Corpus Striatum, Parkinson Disease, Substantia Nigra.
- Aging, Binding Sites, Diagnosis, Differential, Humans, Tomography, Emission-Computed.

Abstract

La tomoscintigraphie est capable de détecter les déficits dopaminergiques, et de faciliter ainsi le diagnostic des diverses formes de parkinsonisme

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The use of PET in Parkinson's disease</title>
<author><name sortKey="Shinotoh, H" sort="Shinotoh, H" uniqKey="Shinotoh H" first="H." last="Shinotoh">H. Shinotoh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. British Columbia, neurodegenerative disorders cent.</s1>
<s2>Vancouver BC V6T 2B5</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver BC V6T 2B5</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">522-95-11842</idno>
<date when="1995">1995</date>
<idno type="stanalyst">FRANCIS 522-95-11842 INIST</idno>
<idno type="RBID">Francis:522-95-11842</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F97</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000C19</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000E46</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000E46</idno>
<idno type="wicri:doubleKey">0278-2626:1995:Shinotoh H:the:use:of</idno>
<idno type="wicri:Area/Main/Merge">004803</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8546856</idno>
<idno type="wicri:Area/PubMed/Corpus">001911</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001911</idno>
<idno type="wicri:Area/PubMed/Curation">001911</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001911</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001911</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001911</idno>
<idno type="wicri:Area/Ncbi/Merge">002513</idno>
<idno type="wicri:Area/Ncbi/Curation">002513</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002513</idno>
<idno type="wicri:doubleKey">0278-2626:1995:Shinotoh H:the:use:of</idno>
<idno type="wicri:Area/Main/Merge">004611</idno>
<idno type="wicri:Area/Main/Curation">004081</idno>
<idno type="wicri:Area/Main/Exploration">004081</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The use of PET in Parkinson's disease</title>
<author><name sortKey="Shinotoh, H" sort="Shinotoh, H" uniqKey="Shinotoh H" first="H." last="Shinotoh">H. Shinotoh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. British Columbia, neurodegenerative disorders cent.</s1>
<s2>Vancouver BC V6T 2B5</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver BC V6T 2B5</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author>
</analytic>
<series><title level="j" type="main">Brain and cognition</title>
<title level="j" type="abbreviated">Brain cogn.</title>
<idno type="ISSN">0278-2626</idno>
<imprint><date when="1995">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain and cognition</title>
<title level="j" type="abbreviated">Brain cogn.</title>
<idno type="ISSN">0278-2626</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (therapeutic use)</term>
<term>Aging</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Binding Sites</term>
<term>Brain (diagnostic imaging)</term>
<term>Brain (metabolism)</term>
<term>Brain (physiopathology)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Diagnosis</term>
<term>Diagnosis, Differential</term>
<term>Humans</term>
<term>Neurology</term>
<term>Neurotransmitter Agents (physiology)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson's disease</term>
<term>Patological physiology</term>
<term>Receptors, Dopamine D2 (physiology)</term>
<term>Substantia Nigra (physiopathology)</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Neurotransmitter Agents</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term>
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aging</term>
<term>Binding Sites</term>
<term>Diagnosis, Differential</term>
<term>Humans</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Physiologie pathologique</term>
<term>Neurologie</term>
<term>Diagnostic</term>
<term>Tomoscintigraphie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Neurologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="fr">La tomoscintigraphie est capable de détecter les déficits dopaminergiques, et de faciliter ainsi le diagnostic des diverses formes de parkinsonisme</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Shinotoh, H" sort="Shinotoh, H" uniqKey="Shinotoh H" first="H." last="Shinotoh">H. Shinotoh</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004081 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004081 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Francis:522-95-11842
   |texte=   The use of PET in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

The use of PET in Parkinson's disease

The use of PET in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.